Status:
WITHDRAWN
HDM201 Added to CT in R/R or Newly Diagnosed AML
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Leukemia, Myeloid, Acute
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is a multi-center open-label Phase I/II study investigating orally administered HDM201 in combination with chemotherapy in two populations: subjects with first line AML or subjects with relapsed/...
Detailed Description
This is a Phase 1 / 2 study. No patients were screened / enrolled. There are no data collected. There will be no CSR.
Eligibility Criteria
Inclusion
- All Subjects
- Signed informed consent must be obtained prior to participation in the study
- Age ≥18
- Diagnosis of AML based on WHO 2016 classification. Patients with APL (acute promyelocytic leukemia) with PML-RARA are not eligible.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) that is 0 - 2.
- Adequate organ functions
- Left ventricular ejection fraction \> 45%
- For 1L AML population:
- For Part 1 or Part 2 Expansion Cohorts 1 or 2: subjects with de novo AML suitable for induction treatment with cytarabine and anthracyclines as per investigator judgement
- For Part 2 Expansion Cohort 2: documented presence of FLT3 mutation (ITD or TKD ) and suitable for midostaurin treatment as per investigator judgement.
- For Part 2 Expansion Cohort 3: Subjects with secondary AML (e.g. AML-MRC , secondary to myelodysplasia/MDS or therapy-related AML). Prior use of hypomethylating agents or other therapies with curative intent for treatment previous hematological malignancies or therapy-related AML is allowed. Subjects suitable for induction treatment with liposomal cytarabine/daunorubicin as per investigator judgement.
- For R/R AML population:
- All Parts: Diagnosis of relapsed or refractory AML and suitable for treatment with IDAC as per investigator judgement.
- For Part 3 only: willingness and suitability to participate in DDI Cohort 1 or 2.
Exclusion
- Prior exposure to MDM2 and MDM4 inhibitor (e.g. idasanutlin)
- Known symptomatic CNS leukemia not controlled by adequate therapy.
- Isolated extramedullary leukemia
- Subjects with prior malignancy (some exceptions apply)
- QTcF \> 470 ms at screening
- Subjects who require treatment with moderate or strong CYP3A4 inducers within 14 days prior to starting study treatment or during the study
- Subjects who require use of herbal preparations/medications and dietary supplements within 7 days prior to first dose and during the study
- Subjects who require treatment with substrates of CYP3A4/5 with narrow therapeutic index (within 24 hours prior to during and 48 hours after HDM201 administration)
- Subjects who require treatment with moderate or strong CYP3A4 inhibitors within 48 hours prior to, during and 48 hours post HDM201 administration. (except for Part 3 DDI Cohort 1 and 2)
- Subject is pregnant or breastfeeding
- WOCBP unless using highly effective methods of contraception during study treatment and for an appropriate time period after last study treatment
- Sexually active males unless they use a condom during intercourse while taking study drug and for an appropriate time period after last study treatment
- For Part 1 only:
- \- Subjects with a known favorable risk AML subtype at screening or subjects with FLT3 mutation
- For Part 3 only:
- DDI Cohort 1: use of posaconazole (other than the planned dosing required by the protocol) within 7 days prior to start of the DDI investigation and for the duration of the DDI period
- DDI Cohort 2: use of midazolam (other than the planned dosing required by the protocol) within 2 days prior to start of the DDI investigation and for the duration of the DDI period
- DDI Cohort 1 and 2: subjects who have received, or are expected to receive moderate or strong inhibitors of CYP3A4 within 7 days prior to start of the DDI investigation, for the duration of the investigation, and 24 hours after last blood sample collection for PK assessment
- Other protocol-defined inclusion/exclusion may apply.
Key Trial Info
Start Date :
November 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 13 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03760445
Start Date
November 15 2019
End Date
June 13 2023
Last Update
January 9 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.